XOMA Corporation (XOMA) has risen sharply, recording gains of 14.8% in the past 4 weeks. However, the stock has corrected -6.11% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 12.01% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
XOMA Corporation (NASDAQ:XOMA): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.60 and $0.60 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.64. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.63, notching a gain of 0.33% for the day. The total traded volume was 407,206 . The stock had closed at $0.63 on the previous day.
The stock has recorded a 20-day Moving Average of 10.62% and the 50-Day Moving Average is 6.17%. XOMA Corporation has dropped 12.5% during the last 3-month period . Year-to-Date the stock performance stands at -52.63%.
XOMA Corporation (XOMA) : Average target price received by XOMA Corporation (XOMA) is $1.62 with an expected standard deviation of $1.2. The most aggressive target on the stock is $3, whereas the most downbeat target is $1. 3 financial analysts are currently covering the stock.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).